EP4698559A1 - Heterodimere antikörper, verwendungen in therapeutischen anwendungen und zusammensetzungen im zusammenhang damit - Google Patents

Heterodimere antikörper, verwendungen in therapeutischen anwendungen und zusammensetzungen im zusammenhang damit

Info

Publication number
EP4698559A1
EP4698559A1 EP24793567.9A EP24793567A EP4698559A1 EP 4698559 A1 EP4698559 A1 EP 4698559A1 EP 24793567 A EP24793567 A EP 24793567A EP 4698559 A1 EP4698559 A1 EP 4698559A1
Authority
EP
European Patent Office
Prior art keywords
heavy chain
mutations
certain embodiments
antibody
disclosure relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24793567.9A
Other languages
English (en)
French (fr)
Inventor
Eric Sundberg
Jonathan DU
Tala AZZAM
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emory University
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University filed Critical Emory University
Publication of EP4698559A1 publication Critical patent/EP4698559A1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EP24793567.9A 2023-04-21 2024-04-19 Heterodimere antikörper, verwendungen in therapeutischen anwendungen und zusammensetzungen im zusammenhang damit Pending EP4698559A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363461078P 2023-04-21 2023-04-21
US202363578789P 2023-08-25 2023-08-25
PCT/US2024/025404 WO2024220805A1 (en) 2023-04-21 2024-04-19 Heterodimeric antibodies, uses in therapeutic applications, and compositions related thereto

Publications (1)

Publication Number Publication Date
EP4698559A1 true EP4698559A1 (de) 2026-02-25

Family

ID=93153380

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24793567.9A Pending EP4698559A1 (de) 2023-04-21 2024-04-19 Heterodimere antikörper, verwendungen in therapeutischen anwendungen und zusammensetzungen im zusammenhang damit

Country Status (6)

Country Link
EP (1) EP4698559A1 (de)
KR (1) KR20250174648A (de)
CN (1) CN120826414A (de)
AU (1) AU2024257364A1 (de)
MX (1) MX2025011792A (de)
WO (1) WO2024220805A1 (de)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
US10745463B2 (en) * 2013-11-18 2020-08-18 University Of Maryland, Baltimore Hyper-glycosylated antibodies with selective Fc receptor binding
EP3722322A4 (de) * 2017-12-04 2021-09-15 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-l1/anti-cd47-bispezifischer antikörper mit einer struktur wie ein natürlicher antikörper und in form eines heterodimers sowie herstellung davon

Also Published As

Publication number Publication date
MX2025011792A (es) 2025-11-03
KR20250174648A (ko) 2025-12-12
CN120826414A (zh) 2025-10-21
WO2024220805A1 (en) 2024-10-24
AU2024257364A1 (en) 2025-08-14

Similar Documents

Publication Publication Date Title
JP7625656B2 (ja) 完全ヒト化抗ｂ細胞成熟抗原（ｂｃｍａ）の単鎖抗体およびその応用
US11639376B2 (en) Constructs having a SIRP-α domain or variant thereof
JP6351572B2 (ja) Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
CN114258400A (zh) 用于改进的单链可变片段的材料和方法
JP7183221B2 (ja) 修飾された抗原結合ポリペプチド構築物及びその使用
JP2021528988A (ja) 新規の二重特異性アゴニスト４−１ｂｂ抗原結合分子
CN113227147B (zh) 全人源的抗cd30单链抗体及其应用
CN115702163A (zh) 异二聚体蛋白质
CN116583300A (zh) 多特异性抗原结合蛋白
WO2018237364A1 (en) Asymmetric heterodimeric fc-scfv fusion anti-globo h and anti-cd3 bispecifc antibody and uses thereof in caner therapy
CA3209827A1 (en) Anti-tnfr2 antibody and use thereof
WO2025133042A2 (en) Activatable fusion proteins and methods of use
EP4698559A1 (de) Heterodimere antikörper, verwendungen in therapeutischen anwendungen und zusammensetzungen im zusammenhang damit
JP7245793B2 (ja) 安定化したキメラＦａｂ
CN117999285A (zh) 包含基于mhc蛋白的异源二聚体的双特异性抗体
WO2024220873A1 (en) Asymmetric antibody glycosylation methods and compositions related thereto
HK40114235A (zh) 激动性ltbr抗体以及包含它们的双特异性抗体
HK40034272B (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof
HK40020709A (en) Stabilized chimeric fabs
HK40034272A (en) Fully human anti-b cell maturation antigen (bcma) single chain variable fragment, and application thereof
HK1237351A1 (en) Modified antigen binding polypeptide constructs and uses thereof

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20251107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR